AR049280A1 - Cristal estable de derivado de 4 - oxoquinolina, su uso como agente anti - hiv y su uso en composiciones anti - hiv. - Google Patents

Cristal estable de derivado de 4 - oxoquinolina, su uso como agente anti - hiv y su uso en composiciones anti - hiv.

Info

Publication number
AR049280A1
AR049280A1 ARP050102058A ARP050102058A AR049280A1 AR 049280 A1 AR049280 A1 AR 049280A1 AR P050102058 A ARP050102058 A AR P050102058A AR P050102058 A ARP050102058 A AR P050102058A AR 049280 A1 AR049280 A1 AR 049280A1
Authority
AR
Argentina
Prior art keywords
hiv
crystal
compositions
oxoquinoline
derivative
Prior art date
Application number
ARP050102058A
Other languages
English (en)
Inventor
M Satoh
T Motomura
T Matsuda
K Kondo
K Ando
K Matsuda
S Miyake
H Uehara
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049280(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of AR049280A1 publication Critical patent/AR049280A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Este cristal posee inhibicion de integrasa y se utiliza como agente anti-HIV y en la preparacion de composiciones anti-HIV que comprenden al mencionado cristal como principio activo. Reivindicacion 1: Un cristal (cristal de forma II) de ácido 6-(3- cloro-2-fluorobencil)-1-[(S)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxílico, caracterizado por que posee un modelo de difraccion de polvo con rayos X que posee crestas de difraccion característica en ángulos de difraccion 2Theta (s) de 6,56; 13,20; 19,86; 20,84; 21,22; 25,22s medido por difractometro de polvo con rayos X.
ARP050102058A 2004-05-20 2005-05-19 Cristal estable de derivado de 4 - oxoquinolina, su uso como agente anti - hiv y su uso en composiciones anti - hiv. AR049280A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004150979 2004-05-20

Publications (1)

Publication Number Publication Date
AR049280A1 true AR049280A1 (es) 2006-07-12

Family

ID=35079161

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP050102058A AR049280A1 (es) 2004-05-20 2005-05-19 Cristal estable de derivado de 4 - oxoquinolina, su uso como agente anti - hiv y su uso en composiciones anti - hiv.
ARP140101722A AR096100A2 (es) 2004-05-20 2014-04-25 Cristal estable de derivado de 4-oxoquinolina, su uso como agente anti-hiv y su uso en composiciones anti-hiv

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP140101722A AR096100A2 (es) 2004-05-20 2014-04-25 Cristal estable de derivado de 4-oxoquinolina, su uso como agente anti-hiv y su uso en composiciones anti-hiv

Country Status (33)

Country Link
US (6) US7635704B2 (es)
EP (4) EP3281939B1 (es)
JP (1) JP3754064B2 (es)
KR (1) KR20080064909A (es)
CN (1) CN1956961B (es)
AR (2) AR049280A1 (es)
AU (1) AU2005245296B2 (es)
BR (1) BRPI0510114B8 (es)
CA (1) CA2566922C (es)
CY (1) CY1113010T1 (es)
DK (2) DK1636190T3 (es)
ES (2) ES2388441T3 (es)
FI (2) FI3281939T3 (es)
FR (1) FR23C1040I1 (es)
HK (1) HK1083341A1 (es)
HR (2) HRP20231588T3 (es)
HU (2) HUE064615T2 (es)
IL (1) IL179250A0 (es)
LT (1) LT3281939T (es)
LU (1) LUC00334I2 (es)
MX (1) MXPA06013405A (es)
MY (1) MY134672A (es)
NO (6) NO339223B1 (es)
NZ (1) NZ551839A (es)
PE (2) PE20120361A1 (es)
PL (2) PL1636190T3 (es)
PT (2) PT3281939T (es)
RS (2) RS52375B (es)
RU (1) RU2330845C1 (es)
SI (2) SI3281939T1 (es)
TW (1) TWI329015B (es)
WO (1) WO2005113508A1 (es)
ZA (1) ZA200610647B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891227B2 (en) 2002-03-20 2005-05-10 International Business Machines Corporation Self-aligned nanotube field effect transistor and method of fabricating same
EP1564210B9 (en) * 2002-11-20 2010-03-31 Japan Tobacco Inc. 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
SG170795A1 (en) 2005-12-30 2011-05-30 Gilead Sciences Inc Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
EP2452682A1 (en) 2006-02-01 2012-05-16 Japan Tobacco, Inc. Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
KR101023635B1 (ko) * 2006-03-06 2011-03-22 니뽄 다바코 산교 가부시키가이샤 4-옥소퀴놀린 화합물 제조 방법
US8420821B2 (en) 2006-03-06 2013-04-16 Japan Tobacco Inc. Process for production of 4-oxoquinoline compound
EP2049506B2 (en) 2006-07-07 2024-05-08 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
AR063710A1 (es) 2006-09-12 2009-02-11 Gilead Sciences Inc Proceso para la preparacion de acido 6-(3-cloro-2-fluorbencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolon-3-carboxilico como inhibidores de integrasa del hiv e intermediarios de sintesis del mismo y composiciones que lo comprenden.
PT2487163T (pt) 2007-02-23 2016-11-21 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
AU2008270630B2 (en) * 2007-06-29 2014-01-16 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
EA200971096A1 (ru) * 2007-06-29 2010-08-30 Джилид Сайэнс, Инк. Терапевтические композиции и их применение
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
MX2010011963A (es) 2008-05-02 2010-12-06 Gilead Sciences Inc Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico.
AU2010210598B2 (en) 2009-02-06 2015-03-05 Gilead Sciences, Inc. Tablets for combination therapy
WO2010137032A2 (en) * 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
CN102212032B (zh) * 2011-04-20 2013-07-31 复旦大学 一种5-羟基喹诺酮类衍生物及其制备方法和用途
WO2014008458A2 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
BR112015002275A2 (pt) 2012-08-03 2017-07-04 Gilead Sciences Inc processos e intermediários para a preparação de inibidores da integrase
CN103819402B (zh) * 2012-11-17 2016-03-30 上海迪赛诺化学制药有限公司 埃替拉韦中间体及其制备方法和应用
CN103864682B (zh) * 2012-12-18 2016-12-28 上海迪赛诺化学制药有限公司 一种制备iii型埃替拉韦晶体的方法
UY35213A (es) 2012-12-21 2014-06-30 Gilead Sciences Inc Compuestos del tipo de las carbamilpiridonas policíclicas y su uso farmaceutico
AU2014286993B2 (en) 2013-07-12 2018-10-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections
NO2865735T3 (es) 2013-07-12 2018-07-21
CN105315203A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种v型埃替拉韦晶体及其制备方法
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (es) 2014-06-20 2018-06-23
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
NZ735575A (en) 2015-04-02 2018-11-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CN106008195B (zh) * 2016-05-19 2018-08-03 绍兴文理学院 一种2，4-二氟-5-碘苯甲酸的制备方法
EP3984536A1 (en) * 2020-10-19 2022-04-20 Centre national de la recherche scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
JPS567162B1 (es) 1970-09-14 1981-02-16
JPS4826772A (es) 1971-08-11 1973-04-09
JPS6450979A (en) 1987-08-21 1989-02-27 Hitachi Shipbuilding Eng Co Method for discriminating whistle sound
JPH0651229B2 (ja) 1989-07-31 1994-07-06 新日本製鐵株式会社 プラズマアーク溶接方法および装置
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
NO304832B1 (no) 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
WO1996002512A1 (fr) 1994-07-18 1996-02-01 Ube Industries, Ltd. Acide du type trifluoromethylquinoleinecarboxylique
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
EP0892801B1 (en) 1996-04-12 2002-01-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Acridone-derived compounds useful as antineoplastic and antiretroviral agents
FR2761687B1 (fr) * 1997-04-08 2000-09-15 Centre Nat Rech Scient Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
GB9721964D0 (en) 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
PE20011349A1 (es) 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6841558B2 (en) 2000-10-12 2005-01-11 Merck & Co., Inc. Aza-and polyaza-naphthalenyl carboxamides useful as HIV intergrase inhibitors
JP2004513134A (ja) 2000-10-12 2004-04-30 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルケトン類
EP2033952B1 (en) 2001-03-01 2012-08-29 Shionogi&Co., Ltd. Nitrogen-containing Heteroaryl compounds having HIV Integrase Inhibitory Activity
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
FR2827600A1 (fr) 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
JP4035765B2 (ja) 2002-10-31 2008-01-23 横河電機株式会社 フーリエ変換型赤外線分光計
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
EP1564210B9 (en) * 2002-11-20 2010-03-31 Japan Tobacco Inc. 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
US7531554B2 (en) * 2004-05-20 2009-05-12 Japan Tobacco Inc. 4-oxoquinoline compound and use thereof as HIV integrase inhibitor
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
JP4629104B2 (ja) 2004-05-21 2011-02-09 日本たばこ産業株式会社 ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤

Also Published As

Publication number Publication date
HRP20120681T1 (hr) 2012-09-30
HK1083341A1 (en) 2006-06-30
NO20190051A1 (no) 2007-02-07
FI3281939T3 (fi) 2023-10-23
KR20080064909A (ko) 2008-07-09
NO20200873A1 (no) 2007-02-07
CA2566922A1 (en) 2005-12-01
TW200600097A (en) 2006-01-01
PT1636190E (pt) 2012-08-20
SI3281939T1 (sl) 2024-02-29
BRPI0510114B1 (pt) 2020-09-15
CN1956961B (zh) 2010-05-26
TWI329015B (en) 2010-08-21
IL179250A0 (en) 2007-03-08
AR096100A2 (es) 2015-12-09
CA2566922C (en) 2011-01-11
SI1636190T1 (sl) 2012-09-28
CY1113010T1 (el) 2016-04-13
HUS2400006I1 (hu) 2024-04-28
FIC20240008I1 (fi) 2024-03-20
RS64845B1 (sr) 2023-12-29
EP1636190B1 (en) 2012-06-27
US20220235009A1 (en) 2022-07-28
FR23C1040I1 (fr) 2023-12-29
MXPA06013405A (es) 2007-03-01
NO339223B1 (no) 2016-11-21
AU2005245296A1 (en) 2005-12-01
ZA200610647B (en) 2008-06-25
CN1956961A (zh) 2007-05-02
EP3281939A1 (en) 2018-02-14
BRPI0510114B8 (pt) 2021-05-25
EP1636190A1 (en) 2006-03-22
JP2006001927A (ja) 2006-01-05
PL3281939T3 (pl) 2024-03-18
EP4299563A3 (en) 2024-02-28
HUE064615T2 (hu) 2024-04-28
PE20120361A1 (es) 2012-05-03
US7635704B2 (en) 2009-12-22
DK3281939T3 (da) 2024-01-22
NO20161297A1 (no) 2007-02-07
LUC00334I2 (es) 2024-07-01
US20060030710A1 (en) 2006-02-09
NZ551839A (en) 2009-11-27
DK1636190T3 (da) 2012-09-24
WO2005113508A1 (en) 2005-12-01
JP3754064B2 (ja) 2006-03-08
RS52375B (en) 2012-12-31
AU2005245296B2 (en) 2010-08-12
PL1636190T3 (pl) 2012-10-31
US20180029989A1 (en) 2018-02-01
NO20065790L (no) 2007-02-07
US8981103B2 (en) 2015-03-17
ES2960824T3 (es) 2024-03-06
BRPI0510114A (pt) 2007-09-25
EP2514746A1 (en) 2012-10-24
NO20230913A1 (no) 2007-02-07
EP3281939B1 (en) 2023-10-18
US20150361044A1 (en) 2015-12-17
US20100204271A1 (en) 2010-08-12
PE20060358A1 (es) 2006-05-12
LT3281939T (lt) 2023-11-27
MY134672A (en) 2007-12-31
NO347902B1 (no) 2024-05-06
US20190185433A1 (en) 2019-06-20
ES2388441T3 (es) 2012-10-15
RU2330845C1 (ru) 2008-08-10
PT3281939T (pt) 2023-11-22
NO20220690A1 (no) 2007-02-07
HRP20231588T3 (hr) 2024-03-15
EP4299563A2 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
AR049280A1 (es) Cristal estable de derivado de 4 - oxoquinolina, su uso como agente anti - hiv y su uso en composiciones anti - hiv.
TW200630326A (en) Chemical compounds
ATE520406T1 (de) Kristalline form des ibandronat-natriums
WO2005085234A3 (en) Bycyclic anthranilamide derivatives useful as insecticides
CY1115190T1 (el) Φαρμακοτεχνικες μορφες αερολυματων περιλαμβανοντας διενυδρη φουμαρικη φορμοτερολη, ενα προωθητικο, αιθανολη και προεραιτικως ενα στεροειδες, οπου η διενυδρη φουμαρικη φορμοτερολη εχει ενα περιεχομενο υδατος του 4,8-4.28% κατα βαρος
HK1064295A1 (en) Medical aerosol formulations
ATE345041T1 (de) Konzentrierte wasserlösliche granulatförmige pflanzenwachstumsregulatorformulierung und verfahren zu ihrer verwendung
JP2004529078A5 (es)
ES2046083B1 (es) Procedimiento para preparar composiciones de liberacion prolongada.
NO20035210L (no) 2-anilino-pyrimidinderivater som cyklinavhengige kinaseinhibitorer
ATE275393T1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
TW200630352A (en) Chemical compounds
HRP20040107B1 (en) Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
HUP0400646A2 (hu) Szteroid hormonkészítmények és előállításukra szolgáló eljárások
NZ593475A (en) Calcium salts for reducing exhalation of infectious bioaerosol particles
ECSP055859A (es) Forma cristalina alfa del renelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
NO20080002L (no) Formuleringer av konjugerte ostrogener og bazedoxifen
SE0401345D0 (sv) Therapeutic compounds: Pyridine as scaffold
EP1113000A4 (en) BENZENE DERIVATIVES AND THEIR MEDICAL APPLICATION
ATE445389T1 (de) Liposomale glucocorticoide
JP2007533712A5 (es)
FR2999086B1 (fr) Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
DE602007010819D1 (de) Verringerung von übergewicht oder fettsucht
PH12019501105A1 (en) Oral care composition
ATE412404T1 (de) Stabile orale pharmazeutische zusammensetzungen von buprenorphin und salz davon

Legal Events

Date Code Title Description
FC Refusal